<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40105884</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2831-090X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Mar</Month><Day>18</Day></PubDate></JournalIssue><Title>Biomolecules &amp; biomedicine</Title><ISOAbbreviation>Biomol Biomed</ISOAbbreviation></Journal><ArticleTitle>Adefovir anticancer potential: Network pharmacology, anti-proliferative &amp; apoptotic effects in HeLa cells.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.17305/bb.2025.12058</ELocationID><Abstract><AbstractText>Cervical cancer presents a significant healthcare challenge due to recurrent disease and drug resistance, highlighting the urgent need for novel therapeutic strategies. Network pharmacology facilitates drug repurposing by elucidating multi-target mechanisms of action. Adefovir, an acyclic nucleotide analog, has shown promising potential in cervical cancer treatment, particularly in HeLa cells. In vitro studies have demonstrated that adefovir inhibits HeLa cell proliferation by enhancing apoptosis while maintaining a low cytotoxicity profile at therapeutic concentrations, making it an attractive candidate for further exploration. A combined network pharmacology and in vitro study was conducted to investigate the molecular mechanism of adefovir against cervical cancer. Potential gene targets for adefovir and cervical cancer were predicted using database analysis. Hub targets were identified, and protein-protein interaction (PPI) networks were constructed. Molecular docking assessed adefovir's binding affinity to key targets. In vitro cytotoxic assays, including 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and crystal violet assays, were performed using 96-well plates to evaluate anti-proliferative effects in HeLa cells. Apoptosis was assessed via p53 immunocytochemistry Enzyme-Linked Immunosorbent Assay (ELISA), while Vascular Endothelial Growth Factor ELISA (VEGF ELISA) was used to measure cell proliferation. Venn analysis identified 144 common targets between adefovir and cervical cancer. Network analysis revealed key hub targets involved in oncogenic pathways. Molecular docking demonstrated strong binding between adefovir and Mitogen-Activated Protein Kinase 3 (MAPK3) and SRC proteins. In vitro, adefovir significantly suppressed HeLa cell viability, with an Inhibitory Concentration 50 (IC50) of 7.8 &#x3bc;M, outperforming 5-Fluorouracil (5-FU). Additionally, it induced apoptosis via p53 activation and inhibited cell proliferation through VEGF suppression. These integrated computational and experimental findings suggest that adefovir exerts multi-targeted effects against cervical cancer. Its promising preclinical efficacy warrants further investigation as a potential alternative therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mateen Azhar</LastName><ForeName>Muzammal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Research in Molecular Medicine, Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maqbool</LastName><ForeName>Tahir</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Centre for Research in Molecular Medicine, Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Fatima</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre for Research in Molecular Medicine, Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altaf</LastName><ForeName>Awais</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Research in Molecular Medicine, Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atif</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The University of Lahore, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Zulfiqar</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Centre for Research in Molecular Medicine, Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan; Lahore Medical and Dental College, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qureshi</LastName><ForeName>Zahid Habib</ForeName><Initials>ZH</Initials><AffiliationInfo><Affiliation>Multan Medical and Dental College, Multan, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naveed</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, Faculty of Science and Technology, University of Central Punjab, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aziz</LastName><ForeName>Tariq</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Animal Health Food Hygiene and Quality University of Ioannina, Arta, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali El Hadi Mohamed</LastName><ForeName>Rania</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, P. O. Box 84428, Riyadh, 11671, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>A Al-Joufi</LastName><ForeName>Fakhria</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, College of Pharmacy, Jouf University, 72341 Aljouf, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S Alwethaynani</LastName><ForeName>Maher</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Alquwayiyah, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Bosnia and Herzegovina</Country><MedlineTA>Biomol Biomed</MedlineTA><NlmUniqueID>9918522188506676</NlmUniqueID><ISSNLinking>2831-0896</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>19</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>19</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>19</Day><Hour>11</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40105884</ArticleId><ArticleId IdType="doi">10.17305/bb.2025.12058</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>